Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy by Paulina Stachyra-Strawa, Lidia Szatkowska-Sieczek, Paweł Cisek, Paweł Gołębiowski, Ludmiła Grzybowska-Szatkowska

Get full text

Programmed Cell Death Protein 1 Inhibitor-Mediated Peripheral Neuropathy by Yanyun Ao, BA, Ming Gao, MM, Binbin Sun, MD, Hongjun Hao, PhD, Huan Yan, MM, Chuntong Li, MD, Decong Sun, MD, Xuejiao Yang, BA, Yanfang Ju, MD, Xia Zhang, MD, Junxun Ma, MD

“…With the continuous deepening of the research on the mechanism of immunotherapy, ICIs, such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 inhibitors and cytotoxic T lymphocyte-associated protein 4 inhibitors, have been widely used in a variety of tumors. …”
Get full text

Novel cutaneous eruptions in the setting of programmed cell death protein 1 inhibitor therapy by Rohan Mital, BS, Alexander M. Cartron, MD, John C. Trinidad, MD, MPH, Natalie Spaccarelli, MD, I-sanna Gibbons-Fideler, MD, Benjamin H. Kaffenberger, MD, MS, Catherine G. Chung, MD

Get full text

Gut Microbiota Modulates the Efficiency of Programmed Cell Death Protein 1 Cancer Immunotherapies by Azam Samei, Mostafa Khedri

“… Program cell death protein 1 (PD1) is considered as an inhibitory molecule that is expressed on the surface of activated T-cells and bound to PD-L1 and PD-L2 ligands. …”
Get full text

Efficacy of programmed cell death protein 1 inhibitor in resection transformation treatment of esophageal cancer by Mengying Fan, Liang Dai, Wanpu Yan, Yongbo Yang, Yao Lin, Keneng Chen

“…Therefore, the aim of this study was to assess the safety and efficacy of chemo/radiotherapy combined with a programmed cell death protein 1 (PD‐1) inhibitor in the preoperative transformation of unresectable esophageal cancer. …”
Get full text

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis by Debasree Banerjee, Sean Monaghan, Runping Zhao, Thomas Walsh, Amy Palmisciano, Gary S. Phillips, Steven Opal, Mitchell M. Levy

Subjects: Get full text

Clinical observation on skin adverse reactions after treatment of programmed cell death protein-1 inhibitors by ZHAO Yang, GUAN Fengjun, HAN Zhengxiang

Subjects: “…programmed cell death protein 1…”
Get full text

Pemphigus Herpetiformis-Type Drug Reaction Caused by Programmed Cell Death Protein-1 Inhibitor Treatment by Zhang Y, Zhang M, Xie J, Wu W, Lu J

Subjects: “…programmed cell death protein-1 inhibitor…”
Get full text

Research progress of programmed cell death protein-1 inhibitor combined with chemotherapy in advanced gastric cancer by LI Yuanyuan, LIU Haipeng, SHEN Yimin, WANG Zhou, XU Wei, CHEN Xiao

Subjects: Get full text

Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities by Konstantinos Tsiakos, Niki Gavrielatou, Ioannis A. Vathiotis, Loukas Chatzis, Stamatios Chatzis, Garyfallia Poulakou, Elias Kotteas, Nikolaos K. Syrigos

“…This review focuses on the effect of programmed cell death protein 1/programmed death-ligand 1 blockade on the outcome of viral infections in cancer patients as well as the potential benefit from the incorporation of immune checkpoint inhibitors (ICIs) in treatment of viral infections.…”
Get full text

Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer by Tao Shen, Liangjing Zhou, Hua Shen, Chengfei Shi, Shengnan Jia, Guo Ping Ding, Liping Cao

“…Immune checkpoint blockade has led to remarkable and durable objective responses in a number of malignancies and antibody-based strategies targeting programmed cell death protein 1 (PD-1) are showing promise where traditional modalities of surgery, radiotherapy, and chemotherapy have failed. …”
Get full text

Formation of eruptive cutaneous squamous cell carcinomas after programmed cell death protein-1 blockade by Rachel L. Marsh, BA, Joanna A. Kolodney, MD, Sanjana Iyengar, MD, Ahmed Yousaf, BA, B. Asher Louden, MD, Abdullah Al-Bouri, MD, Michael S. Kolodney, MD, PhD

Get full text

Research progress of programmed cell death protein-1 gene polymorphism and its role in hepatocellular carcinoma by LI Zhuyu, TAO Jianan

Subjects: “…programmed cell death protein-1…”
Get full text

Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder by Arbil Acikalin, Emine Bagir, Merve Inceman, Mutlu Deger, Seyda Erdogan

“…Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been approved for urothelial carcinoma, but their use for small-cell carcinoma (SmCC) of the urinary bladder is unclear. …”
Get full text

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition by Samy Hakroush, Sarah Birgit Kopp, Désirée Tampe, Ann-Kathrin Gersmann, Peter Korsten, Michael Zeisberg, Michael Zeisberg, Björn Tampe

Subjects: “…programmed cell death protein 1-ligand 1 (PD-L1)…”
Get full text

Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review by Yu-Quan Li, Xue-Mei Chen, Gui-Fei Si, Xue-Min Yuan

Subjects: Get full text

Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma by Jun Won Kim, Ik Jae Lee

Get full text

Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade by Ioannis A. Vathiotis, Leonidas Salichos, Sandra Martinez-Morilla, Niki Gavrielatou, Thazin Nwe Aung, Saba Shafi, Pok Fai Wong, Shlomit Jessel, Harriet M. Kluger, Konstantinos N. Syrigos, Sarah Warren, Mark Gerstein, David L. Rimm

“…Here, we obtained transcriptomic information from a total of 105 baseline tumor samples comprising two cohorts of patients with advanced melanoma treated with programmed cell death protein 1 (PD-1)-based immunotherapies. …”
Get full text

Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy by Min Deng, Shaohua Li, Qiaoxuan Wang, Rongce Zhao, Jingwen Zou, Wenping Lin, Jie Mei, Wei Wei, Rongping Guo

“…Objective There is a lack of effective treatment to improve the prognosis of intrahepatic cholangiocarcinoma (ICC). Programmed cell death protein-1 (PD-1)-targeted immunotherapy has shown promising results in a variety of malignant tumours. …”
Get full text

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma by Dai Ogata, Lauren E. Haydu, Isabella C. Glitza, Sapna P. Patel, Hussein A. Tawbi, Jennifer L. McQuade, Adi Diab, Suhendan Ekmekcioglu, Michael K. Wong, Michael A. Davies, Rodabe N. Amaria

“…Abstract Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. …”
Get full text